Formycon AG
XETRA:FYB

Watchlist Manager
Formycon AG Logo
Formycon AG
XETRA:FYB
Watchlist
Price: 52.5 EUR 2.34% Market Closed
Market Cap: 927.2m EUR
Have any thoughts about
Formycon AG?
Write Note

Formycon AG
Cash Interest Paid

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Formycon AG
Cash Interest Paid Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash Interest Paid CAGR 3Y CAGR 5Y CAGR 10Y
Formycon AG
XETRA:FYB
Cash Interest Paid
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
BioNTech SE
NASDAQ:BNTX
Cash Interest Paid
€5.4m
CAGR 3-Years
11%
CAGR 5-Years
22%
CAGR 10-Years
N/A
MorphoSys AG
XETRA:MOR
Cash Interest Paid
€1.2m
CAGR 3-Years
-10%
CAGR 5-Years
28%
CAGR 10-Years
N/A
CureVac NV
NASDAQ:CVAC
Cash Interest Paid
€2.4m
CAGR 3-Years
-35%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Immatics NV
NASDAQ:IMTX
Cash Interest Paid
€290k
CAGR 3-Years
-1%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Biotest AG
XETRA:BIO
Cash Interest Paid
€24.2m
CAGR 3-Years
30%
CAGR 5-Years
15%
CAGR 10-Years
-2%
No Stocks Found

Formycon AG
Glance View

Market Cap
927m EUR
Industry
Biotechnology

Formycon AG engages in the manufacture of biosimilar drugs and formulations. The company is headquartered in Martinsried, Bayern and currently employs 159 full-time employees. The company went IPO on 2010-12-20. Its business activities are focused on the development and marketing of biopharmaceuticals that are similar to existing drugs, for which the patent protection is expiring. The firm focuses on treatments in the area of ophthalmology, immunology and other chronic diseases, covering all steps of biosimilar development process, from early-stage analysis of the originator drug to the preclinical and clinical testing phases, as well as the preparation of dossiers for marketing approval. Its biosimilar product pipeline consists of four candidates in pre-clinical and clinical testing phases, including FYB201, a biosimilar candidate for Lucentis; FYB202, a biosimilar candidate for Stelara; FYB203, a biosimilar candidate for Eylea, and FYB205.

FYB Intrinsic Value
77.46 EUR
Undervaluation 32%
Intrinsic Value
Price

See Also

Back to Top